Innovative therapy for hemophilia and Fabry disease in the High-Cost Nosologies program
The Ministry of Health Commission will consider lonocotocog alfa and pegunigalsidase alfa for the High-Cost Nosologies program. Find out why inclusion is important for patients and what obstacles have arisen.
